1 The MDR phenotype is defined as resistance at least to isoniazid
and rifampicin the two most effective drugs recommended by the WHO for the first-line treatment of TB with or without resistance to any other first line anti tubercular drugs.
These include isoniazid
, rifampicin, pyrazinamide, ethambutol and streptomycin.
tuberculosis that is running the activation of isoniazid
[14,15] Mutations in katG gene encoding the catalase-peroxidase enzyme is often associated with the emergence of resistance to INH in M.
Seven persons initiated 9-month daily isoniazid
treatment, and six completed all 9 months of treatment; one person discontinued treatment for unknown reasons.
tuberculosis infection resistant to a single antituberculosis drug, MDR-TB as resistant to both isoniazid
and rifampicin, and poly-resistant TB as resistant to more than one anti-tuberculosis drug (other than the combination of isoniazid
Lupus vulgaris resistant to streptomyc in isoniazid
preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: A prospective cohort.
Three separate studies by Sajduda (2004), Yang (2005), and Feuerriegel (2009) examined the association between mutations in inhA-15 and katG315 and isoniazid
In the present study maximum number of patients showed resistance to Rifampicin (10) followed by Streptomycin (9) Resistance to both Isoniazid
and Rifampicin (MDR) was seen in 6 patients.
9%) orally for 30 days; in Group B mice were given isoniazid
100 mg/kg daily dissolved in 10 ml distilled water orally for 30 days; the animals were sacrificed the next day after the ex- perimental period.
tuberculosis resistant to isoniazid
and ethambutol; a modified treatment regime resolved the infection, and the patient was released the following month, by which time his smear and culture results were negative.
and rifampin, the two front-line TB drugs, came into use in 1952 and 1967 respectively, new TB infections still occur at the rate of roughly one per second.
Published in the online journal Nature Communications, the researchers were looking at how TB becomes resistant to isoniazid
, a first line TB drug.
Out of these 41 isolates, 21 (51%) were resistant to isoniazid
(INH) and rifampicin (RIF) and remaining have different drug resistance patterns.
The standard short-course chemotherapy for treatment of cutaneous tuberculosis which involves the administration of three antituberculous drugs for the first two months (isoniazid
10 mg/Kg, rifampicin10 mg/Kg, pyrazinamide 30 mg/Kg), followed by four months of isoniazid
and rifampicin was started.